What are the indications for prophylactic Low Molecular Weight Heparin (LMWH) in pregnant women with a history of thromboembolic events or other risk factors?

Indications for Prophylactic LMWH in Pregnancy

Prophylactic LMWH is indicated in pregnancy for women with prior unprovoked or hormone-related VTE, antithrombin deficiency with family history of VTE, combined thrombophilias, homozygosity for factor V Leiden or prothrombin gene mutation, severe ovarian hyperstimulation syndrome, and selected high-risk postpartum scenarios including cesarean section with multiple risk factors. 1

History of Prior VTE

Strong Indications for Antepartum Prophylaxis

• Women with prior unprovoked VTE or pregnancy/estrogen-related VTE should receive antepartum prophylactic or intermediate-dose LMWH throughout pregnancy 1
• Women with multiple prior unprovoked VTE episodes not on long-term anticoagulation require antepartum prophylactic or intermediate-dose LMWH 1
• Women on long-term vitamin K antagonists should receive adjusted-dose LMWH (75% of therapeutic dose) throughout pregnancy 1

Low-Risk Prior VTE (Clinical Vigilance Only)

• Women with single VTE associated with a transient, resolved, non-hormonal risk factor (e.g., surgery, trauma) can be managed with clinical surveillance alone during pregnancy, though postpartum prophylaxis is still recommended 1

Thrombophilia-Related Indications

High-Risk Thrombophilias Requiring Prophylaxis

• Antithrombin deficiency with family history of VTE warrants both antepartum and postpartum prophylaxis (strong recommendation) 1
• Homozygosity for factor V Leiden mutation requires antepartum and postpartum prophylaxis regardless of family history 1
• Homozygosity for prothrombin gene mutation requires postpartum prophylaxis; antepartum prophylaxis is suggested if family history present 1
• Combined thrombophilias (compound heterozygosity) warrant antepartum and postpartum prophylaxis regardless of family history 1

Lower-Risk Thrombophilias (Generally No Prophylaxis)

• Heterozygosity for factor V Leiden or prothrombin gene mutation with family history of VTE does NOT require antepartum prophylaxis, though postpartum prophylaxis may be considered 1
• Protein C or protein S deficiency without prior VTE generally requires only postpartum prophylaxis if family history present 1

Important caveat: The American Society of Hematology guidelines emphasize that isolated thrombophilia without prior VTE or family history generally does not warrant antepartum prophylaxis, as the absolute risk remains low. 1

Assisted Reproductive Technology

• Routine thromboprophylaxis is NOT recommended for unselected women undergoing assisted reproduction 1
• Women who develop severe ovarian hyperstimulation syndrome should receive prophylactic LMWH for 3 months post-resolution 1

Postpartum Prophylaxis After Cesarean Section

Standard Cesarean Without Risk Factors

• Early mobilization only; pharmacologic prophylaxis NOT recommended 1

Cesarean With Additional Risk Factors

• Women with one major risk factor or at least two minor risk factors should receive prophylactic LMWH or mechanical prophylaxis (if anticoagulation contraindicated) during hospitalization 1
• Major risk factors include: prior VTE, thrombophilia, obesity (BMI ≥30), smoking >10 cigarettes/day, preeclampsia, emergency cesarean 1
• Extended prophylaxis up to 6 weeks postpartum is suggested for women with persistent multiple risk factors after discharge 1

Universal Postpartum Prophylaxis for Prior VTE

• All women with any history of prior VTE should receive 6 weeks of postpartum prophylaxis with prophylactic or intermediate-dose LMWH, or warfarin (INR 2.0-3.0) 1

Mechanical Heart Valves

• Women with mechanical heart valves require antepartum and postpartum thromboprophylaxis, though specific regimens remain controversial and should involve cardiology consultation 2

Superficial Vein Thrombosis

• Proven acute superficial vein thrombosis in pregnancy warrants treatment with LMWH rather than observation alone 1

Practical Dosing Considerations

• LMWH is preferred over unfractionated heparin for all prophylactic indications in pregnancy (Grade 1B) 1, 3
• Prophylactic dosing typically uses standard weight-based dosing (e.g., enoxaparin 40 mg daily or dalteparin 5000 units daily) 4, 5
• Intermediate dosing uses approximately 50% of therapeutic dose 1
• Routine anti-Xa monitoring is NOT recommended for prophylactic dosing 1, 6
• LMWH should be discontinued at least 24 hours before planned delivery or neuraxial anesthesia 1

Key Pitfalls to Avoid

• Do not withhold prophylaxis in women with prior unprovoked VTE simply because they are not on long-term anticoagulation outside pregnancy—pregnancy itself dramatically increases recurrence risk 1
• Do not use vitamin K antagonists during the first trimester due to teratogenicity risk 1, 3
• Do not prescribe prophylaxis for isolated heterozygous thrombophilia without prior VTE or strong family history—this represents overtreatment 1
• Do not continue LMWH up to the time of delivery if neuraxial anesthesia is planned—allow 24-hour washout period 1